REMOVAL OF ZINC IS REQUIRED FOR PROCESSING OF THE MATURE NUCLEOCAPSID PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS, TYPE-1, BY THE VIRAL PROTEASE

被引:0
|
作者
WONDRAK, EM
SAKAGUCHI, K
RICE, WG
KUN, E
KIMMEL, AR
LOUIS, JM
机构
[1] NIDDK,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892
[2] NCI,CELL BIOL LAB,BETHESDA,MD 20892
[3] NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,ANTIVIRAL DRUG MECHANISMS LAB,FREDERICK,MD 21702
[4] SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,ENVIRONM TOXICOL & CHEM LAB,TIBURON,CA 94920
[5] SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,OCTAMER INC,TIBURON,CA 94920
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In human immunodeficiency virus, RNA selection and packaging during assembly involve the two retroviral-type fingers of the nucleocapsid protein that are held in a constrained configuration by coordinated zinc ions, In this report, we demonstrate that the nucleocapsid protein in a metal bound state is resistant to cleavage by the viral protease, but upon removal of zinc ions by chelating agents, it is hydrolyzed within the first zinc finger between Phe-16 and Asn-17. However, 3-nitrosobenzamide and cupric ions, which release zinc through oxidation of the cysteine residues of the finger, render the nucleocapsid protein resistant to cleavage. Since protease inhibitors and 3-nitrosobenzamide restrict processes relating to steps early in infection, the cleavage of the nucleocapsid protein may represent an essential event that can be exploited for the design of novel antiviral agents.
引用
收藏
页码:21948 / 21950
页数:3
相关论文
共 50 条
  • [31] NEUTRALIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY COMPLEMENT OCCURS BY VIRAL LYSIS
    SPEAR, GT
    SULLIVAN, BL
    LANDAY, AL
    LINT, TF
    JOURNAL OF VIROLOGY, 1990, 64 (12) : 5869 - 5873
  • [32] FUNCTIONAL DOMAINS OF THE CAPSID PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    DORFMAN, T
    BUKOVSKY, A
    OHAGEN, A
    HOGLUND, S
    GOTTLINGER, HG
    JOURNAL OF VIROLOGY, 1994, 68 (12) : 8180 - 8187
  • [33] ANGIOGENIC PROPERTIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TAT PROTEIN
    ALBINI, A
    BARILLARI, G
    BENELLI, R
    GALLO, RC
    ENSOLI, B
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (11) : 4838 - 4842
  • [34] TRANSCELLULAR TRANSACTIVATION BY THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TAT PROTEIN
    HELLAND, DE
    WELLES, JL
    CAPUTO, A
    HASELTINE, WA
    JOURNAL OF VIROLOGY, 1991, 65 (08) : 4547 - 4549
  • [35] PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF RECOMBINANT SIMIAN IMMUNODEFICIENCY VIRUS PROTEASE AND COMPARISON TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE
    GRANT, SK
    DECKMAN, IC
    MINNICH, MD
    CULP, J
    FRANKLIN, S
    DREYER, GB
    TOMASZEK, TA
    DEBOUCK, C
    MEEK, TD
    BIOCHEMISTRY, 1991, 30 (34) : 8424 - 8434
  • [36] MAPPING OF FUNCTIONALLY IMPORTANT RESIDUES OF A CYSTEINE-HISTIDINE BOX IN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 NUCLEOCAPSID PROTEIN
    DORFMAN, T
    LUBAN, J
    GOFF, SP
    HASELTINE, WA
    GOTTLINGER, HG
    JOURNAL OF VIROLOGY, 1993, 67 (10) : 6159 - 6169
  • [37] CHARACTERIZATION OF AN ACTIVE SINGLE POLYPEPTIDE FORM OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE
    DIIANNI, CL
    DAVIS, LJ
    HOLLOWAY, MK
    HERBER, WK
    DARKE, PL
    KOHL, NE
    DIXON, RAF
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1990, 265 (28) : 17348 - 17354
  • [38] DESIGN OF TIGHT-BINDING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE INHIBITORS
    VACCA, JP
    RETROVIRAL PROTEASES, 1994, 241 : 311 - 334
  • [39] MUTAGENESIS OF PROTEASE CLEAVAGE SITES IN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GAG POLYPROTEIN
    TRITCH, RJ
    CHENG, YSE
    YIN, FH
    ERICKSONVIITANEN, S
    JOURNAL OF VIROLOGY, 1991, 65 (02) : 922 - 930
  • [40] ASSEMBLY, PROCESSING, AND INFECTIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GAG MUTANTS
    WANG, CT
    BARKLIS, E
    JOURNAL OF VIROLOGY, 1993, 67 (07) : 4264 - 4273